Vertex Pharmaceuticals Incorporated (VRTX) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Vertex Pharmaceuticals Incorporated (VRTX) Healthcare & Pipeline Overview

Vertex Pharmaceuticals Incorporated is a biotechnology leader specializing in cystic fibrosis (CF) therapies, marketing drugs like TRIKAFTA, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO. With a strong profit margin of 35.4% and a robust pipeline including treatments for AAT deficiency, kidney diseases, Type 1 Diabetes, and pain, Vertex is expanding beyond CF.

What Is the Investment Thesis for VRTX?

Vertex Pharmaceuticals Incorporated presents a notable research candidate based on its dominant position in the CF market and its expanding pipeline. The company's existing CF franchise generates substantial revenue and profits, reflected in its impressive 35.4% profit margin. Growth catalysts include the potential approval and commercialization of VX-864 for AAT deficiency, VX-147 for APOL1-mediated kidney diseases, VX-880 for Type 1 Diabetes, VX-548 for pain, and CTX001 for SCD and TDT. These pipeline assets address significant unmet medical needs and could drive substantial revenue growth in the coming years. However, potential risks include clinical trial failures, regulatory hurdles, and competition from other companies developing therapies for the same indications. The company's P/E ratio of 27.8 reflects investor expectations for continued growth.

Based on FMP financials and quantitative analysis

VRTX Key Highlights

Market capitalization of $140B, reflecting its dominant position in the cystic fibrosis market.

• Profit margin of 35.4%, indicating strong profitability and efficient operations.
• Gross margin of 86.3%, showcasing the high value and pricing power of its therapies.
• Beta of 0.37, suggesting lower volatility compared to the overall market.
• No dividend yield, as the company reinvests its earnings into research and development to fuel future growth.

Who Are VRTX's Competitors?

VRTX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are VRTX's Key Strengths?

Dominant position in the cystic fibrosis market.

• Strong pipeline of novel therapies in development.
• High profit margins and strong financial performance.
• Experienced management team and skilled workforce.

What Are VRTX's Weaknesses?

Reliance on the CF market for the majority of its revenue.

• Potential for clinical trial failures and regulatory setbacks.
• Competition from other companies developing therapies for the same indications.
• High drug prices may face increasing scrutiny.

What Could Drive VRTX Stock Higher?

Phase 3 trial results for CTX001 in SCD and TDT.

• Data readouts from Phase 2 trials of VX-864 for AAT deficiency.
• Continued expansion of TRIKAFTA usage to younger age groups.
• Progress in clinical trials for VX-147 in APOL1-mediated kidney diseases.
• Development of VX-548 for acute and chronic pain management.

What Are the Key Risks for VRTX?

Insider selling — insiders were net sellers of roughly $5.6M recently.

• Clinical trial failures for pipeline candidates.
• Regulatory delays or rejections for new therapies.
• Competition from other companies developing therapies for the same indications.
• Dependence on the CF market for a significant portion of revenue.
• Changes in healthcare regulations and reimbursement policies.

What Are the Growth Opportunities for VRTX?

• Expansion into Alpha-1 Antitrypsin Deficiency (AAT): Vertex is developing VX-864 for the treatment of AAT deficiency, a genetic disorder that can cause lung and liver disease. The AAT deficiency market represents a significant growth opportunity for Vertex, with an estimated prevalence of 1 in 3,000 to 5,000 individuals in the United States and Europe. The Phase 2 clinical trial results are expected to be a catalyst. Successful development and commercialization of VX-864 could generate substantial revenue and expand Vertex's presence beyond cystic fibrosis.
• Targeting APOL1-Mediated Kidney Diseases: Vertex is advancing VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney diseases. APOL1-mediated kidney diseases are a significant cause of kidney failure, particularly in individuals of African descent. The market for these therapies is substantial, with a high unmet medical need. VX-147 is currently in Phase 2 clinical trial, and positive results could accelerate its development and commercialization, providing Vertex with a valuable asset in the kidney disease space.
• Developing a Treatment for Type 1 Diabetes: Vertex is developing VX-880 as a potential treatment for Type 1 Diabetes, an autoimmune disease that destroys insulin-producing cells in the pancreas. VX-880 is currently in Phase 1/2 clinical trial. The Type 1 Diabetes market is large and underserved, with millions of patients worldwide. Successful development of VX-880 could transform the treatment paradigm for Type 1 Diabetes and generate significant revenue for Vertex.
• Advancing Pain Management Therapies: Vertex is developing VX-548, a NaV1.8 inhibitor, for the treatment of acute, neuropathic, and musculoskeletal pain. The pain management market is a large and growing market, driven by the aging population and the increasing prevalence of chronic pain conditions. VX-548 is currently in Phase 2 clinical trial, and positive results could position it as a non-opioid alternative for pain relief, addressing a critical need in the market.
• Gene Editing Therapies for Sickle Cell Disease and TDT: Vertex is collaborating with CRISPR Therapeutics AG to develop CTX001, a gene-editing therapy for the treatment of severe sickle cell disease (SCD) and transfusion-dependent thalassemia (TDT). These genetic blood disorders affect millions of people worldwide. CTX001 is currently in Phase 3 clinical trial, and positive results could lead to its approval and commercialization, providing a potentially curative therapy for these debilitating diseases.

What Opportunities Does VRTX Have?

• Expansion into new therapeutic areas beyond cystic fibrosis.
• Potential for strategic acquisitions and collaborations.
• Growing demand for innovative therapies for serious diseases.
• Advancements in gene editing and personalized medicine.

What Threats Does VRTX Face?

• Patent expirations and generic competition.
• Changes in healthcare regulations and reimbursement policies.
• Economic downturns and reduced healthcare spending.
• Unexpected safety issues or adverse events with its therapies.

What Are VRTX's Competitive Advantages?

• Patent protection for its CFTR modulator therapies.
• Dominant market share in the CF treatment landscape.
• Strong brand recognition and reputation among healthcare professionals and patients.
• Extensive research and development capabilities.
• Strategic collaborations with leading biotechnology companies.

What Does VRTX Do?

Founded in 1989 and headquartered in Boston, Massachusetts, Vertex Pharmaceuticals Incorporated is a global biotechnology company dedicated to developing and commercializing innovative therapies for serious diseases. Initially focused on various therapeutic areas, Vertex strategically shifted its focus to cystic fibrosis (CF) in the late 1990s. This strategic pivot led to the development of groundbreaking CFTR modulators that address the underlying cause of CF in patients with specific genetic mutations. Vertex's marketed products, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, have transformed the treatment landscape for CF patients with specific mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. TRIKAFTA, its most recent and impactful CF therapy, is approved for patients with CF aged 6 years and older who have at least one F508del mutation, covering a significant portion of the CF patient population. Beyond CF, Vertex is actively expanding its pipeline into other therapeutic areas, including alpha-1 antitrypsin deficiency (AAT), APOL1-mediated kidney diseases, Type 1 Diabetes, pain management, sickle cell disease (SCD), and transfusion-dependent thalassemia (TDT). These programs are in various stages of clinical development, demonstrating Vertex's commitment to addressing unmet medical needs in multiple disease areas. The company sells its products primarily through specialty pharmacies and distributors in the United States and internationally, ensuring access to its therapies for patients worldwide. Vertex collaborates with numerous biotechnology companies, including CRISPR Therapeutics AG and Moderna, Inc., to advance its research and development efforts.

What Products and Services Does VRTX Offer?

• Develops and commercializes therapies for cystic fibrosis (CF).
• Markets TRIKAFTA for CF patients aged 6 years and older with at least one F508del mutation.
• Sells SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO for CF patients with specific mutations.
• Develops VX-864 for the treatment of AAT deficiency.
• Develops VX-147 for the treatment of APOL1-mediated kidney diseases.
• Develops VX-880, treatment for Type 1 Diabetes.
• Develops VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain.
• Develops CTX001 for the treatment severe SCD and TDT.

How Does VRTX Make Money?

• Develops and patents novel pharmaceutical therapies.
• Conducts clinical trials to demonstrate safety and efficacy.
• Obtains regulatory approvals from agencies like the FDA.
• Manufactures and markets its approved therapies globally.
• Collaborates with other companies to expand its research and development efforts.

What Industry Does VRTX Operate In?

Vertex Pharmaceuticals Incorporated operates within the biotechnology industry, a sector characterized by high innovation, intense competition, and significant regulatory oversight. The market for CF therapies is currently dominated by Vertex, but other companies are developing competing treatments. The broader biotechnology industry is experiencing rapid growth, driven by advances in genomics, personalized medicine, and gene editing. Vertex's expansion into new therapeutic areas positions it to capitalize on these trends and diversify its revenue streams. The company's collaborations with other biotechnology companies enhance its research and development capabilities and provide access to new technologies.

Who Are VRTX's Key Customers?

• Patients with cystic fibrosis (CF).
• Patients with Alpha-1 Antitrypsin Deficiency (AAT).
• Patients with APOL1-mediated kidney diseases.
• Patients with Type 1 Diabetes.
• Patients suffering from acute, neuropathic, and musculoskeletal pain.

Over the past six months, Vertex Pharmaceuticals Incorporated insiders filed 30 SEC Form 4 transactions — 16 sales and 14 purchases. On net that is roughly 9K shares disposed (about $5.6M), a signal worth weighing alongside the fundamentals.

Wall Street analysts project Vertex Pharmaceuticals Incorporated revenue of about $13.20B for fiscal 2026, with EPS near $18.77. The estimate reflects 13 contributing analysts.

Vertex Pharmaceuticals Incorporated has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 1.8% above estimates on average.

Vertex Pharmaceuticals Incorporated's Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 13.48 places it in the safe zone, indicating low near-term bankruptcy risk.

Return on equity for Vertex Pharmaceuticals Incorporated stands at 23.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 16.1%, showing how much profit it generates from its asset base. VRTX trades at a trailing price-to-earnings ratio of 27.83, above the Healthcare sector average of ~23x. Its free cash flow yield is 2.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.19 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 3.2%, the inverse of the P/E and a quick read on earnings relative to price.

Vertex Pharmaceuticals Incorporated (VRTX) Valuation Context

Valued at $140B, VRTX is classified as a large-cap stock. Relative to its peer group, VRTX's quantitative score of 98/100 is above the peer average of 71/100.

VRTX Revenue & Earnings Trend

In Q2 2026, VRTX generated $3.33B in top-line revenue, marking a sequential increase of 11.6%. The company recorded net income of $1.10B, with diluted EPS of $4.31. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, VRTX averaged $4.29 in diluted EPS.

Company Profile

Vertex Pharmaceuticals Incorporated operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Boston, US. The company is led by CEO Reshma Kewalramani. VRTX has traded publicly since 1991.

VRTX Financials

VRTX Latest News

VRTX Analyst Consensus

VRTX MoonshotScore

Latest Vertex Pharmaceuticals Incorporated Analysis

Related Investment Themes

Common Questions About VRTX (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources